Table 1 Baseline characteristic of trials participants
From: Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
Source | No. of patients | Gender (male) | Mean age, y | Pre-existent diseases | Diabetes | Total cholesterol (mmol/L) |
|---|---|---|---|---|---|---|
BIP study [8] (2000) | 3090 | 2825 (91%) | 60 | MI more than 6 month, and less than 5 year and/or stable angina | 10% | 5.5 |
VA-HIT study [10] (1999) | 2531 | 2531 (100%) | 64 | Histories of CHD | 25% | 4.5 |
Acheson J [17] (1972) | 95 | 65 (68%) | NR | Cerebral vascular disease | Excluded severe diabetics | 7.5 |
Veterans Administration Cooperative Study Group [18] (1973) | 532 | 532 (100%) | NR | cerebral I or TIA within 12 month | 24% | 6.2 |
Coronary Drug Project Research Group [19] (1975) | 3892 | 3892 (100%) | NR | MI more than 3 month | NR | 6.5 |
WHO-COOP committee of principal Investigators [20] (1978) | 10627 | 10627 (100%) | 46 | Upper third level of cholesterol from 15 745 healthy men | 0% | 6.4 |
1568 | 1568 (100%) | 68 | lower extremity arterial disease | 66% | 5.6 | |
E J Whitney [23] (2005) | 9795 | 6138 (63%) | 62 | Type 2 diabetes mellitus | 100% | 5.0 |
FIELD study [24] (2005) | 143 | 132 (92%) | 63 | Low HDL-C and coronary disease | NR | 5.1 |
The ACCORD Study Group [25] (2010) | 5518 | 3824 (69%) | 62 | Type 2 diabetes mellitus | 100% | 5.0 |